Advertisement
Home Day 3

Day 3

Examining Venetoclax-Based Regimen in Previously Untreated CLL

Time-limited treatment with bendamustine, rituximab, and venetoclax was associated with high rates of undetectable minimal residual disease (MRD) remission in a phase...

Ibrutinib Plus FCR Could Provide Functional Cure in Young CLL Patients

At more than three years of follow-up, most patients with chronic lymphocytic leukemia (CLL) who were treated with a combination of ibrutinib...

Research Supports Post-Transplant Cyclophosphamide and Tacrolimus for GVHD in Older Adults

The combination of post-transplant cyclophosphamide and tacrolimus (PTCy-TK) outperformed conventional graft-versus-host disease (GVHD) prophylaxis in patients undergoing allogeneic hematopoietic cell transplantation (alloHCT),...

Frontline Ibrutinib Plus Venetoclax Induces Deep Responses in Chronic Lymphocytic Leukemia

According to a study presented at the 2021 American Society of Hematology Annual Meeting, frontline treatment with ibrutinib in combination with venetoclax...
Advertisement
Advertisement